(Total Views: 429)
Posted On: 09/29/2025 10:21:50 PM
Post# of 157588
From our AACR abstract...
Conclusions:
CCR5 may promote ICI resistance in TNBC by upregulating immune checkpoints (sB7H3) and sTyro3. ∼18% of patients with mTNBC treated with leronlimab in combination, or subsequently, with (ICI are currently alive (median >60 months). Leronlimab is well tolerated and induces PD-L1 expression on CAML/CTC, which may prime tumors for successful PD-L1 blockade. The encouraging long-term survival justifies further evaluation of leronlimab in combination with ICIs.
I believe it should read "∼18% of patients with mTNBC treated with leronlimab are currently alive (median >60 months)."
Sorry for being critical but why are we always so sloppy in our scientific presentations?
https://aacrjournals.org/cancerimmunolres/art...onlimab-is
Conclusions:
CCR5 may promote ICI resistance in TNBC by upregulating immune checkpoints (sB7H3) and sTyro3. ∼18% of patients with mTNBC treated with leronlimab in combination, or subsequently, with (ICI are currently alive (median >60 months). Leronlimab is well tolerated and induces PD-L1 expression on CAML/CTC, which may prime tumors for successful PD-L1 blockade. The encouraging long-term survival justifies further evaluation of leronlimab in combination with ICIs.
I believe it should read "∼18% of patients with mTNBC treated with leronlimab are currently alive (median >60 months)."
Sorry for being critical but why are we always so sloppy in our scientific presentations?
https://aacrjournals.org/cancerimmunolres/art...onlimab-is
(4)
(0)
